Peyrin-Biroulet, LaurentLaurentPeyrin-BirouletAllegretti, Jessica RJessica RAllegrettiRubin, David TDavid TRubinBressler, BrianBrianBresslerGerminaro, MatthewMatthewGerminaroHuang, Kuan-Hsiang GaryKuan-Hsiang GaryHuangShipitofsky, NicoleNicoleShipitofskyZhang, HongyanHongyanZhangWilson, RebbeccaRebbeccaWilsonHan, ChenglongChenglongHanFeagan, Brian GBrian GFeaganSandborn, William JWilliam JSandbornPanés, JulianJulianPanésHisamatsu, TadakazuTadakazuHisamatsuLichtenstein, Gary RGary RLichtensteinSands, Bruce EBruce ESandsDignass, AxelAxelDignassSHU-CHEN WEI2024-03-212024-03-212023-1200165085https://www.scopus.com/record/display.uri?eid=2-s2.0-85174843526&doi=10.1053%2fj.gastro.2023.08.038&origin=inward&txGid=15e89240987763955bfaaf167d395854https://scholars.lib.ntu.edu.tw/handle/123456789/641209The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy.enAdvanced Therapy; Interleukin-23p19 Subunit Antagonist; QUASAR; Ulcerative Colitis[SDGs]SDG3journal article10.1053/j.gastro.2023.08.038376596732-s2.0-85174843526https://api.elsevier.com/content/abstract/scopus_id/85174843526